Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multimodality cetuximab-based treatment with CRS and HIPEC for wild-type RAS colorectal or appendiceal peritoneal carcinomatosis
2009-014040-11Phase 2Completed
- Sponsor
- University of Regensburg
- Start
- Jul 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, oxaliplatin, fluorouracil, folinic acid and irinotecan in colorectal cancer (CRC), appendiceal adenocarcinoma and peritoneal carcinomatosis (PC), sponsored by University of Regensburg. Primary endpoint: Progression-free survival. Started Jul 2010; status: completed.
02
Drugs
cetuximaboxaliplatinfluorouracilfolinic acidirinotecan
03
Conditions
colorectal cancer (CRC)appendiceal adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on 2009-014040-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014040-11.